AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)


The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokes and atrial cardiopathy to see which is better at prevention of future strokes.

The use of apixaban for stroke prevention in ischemic stroke patients, without atrial fibrillation, is not approved by the U.S. Food and Drug Administration (FDA) and is considered investigational in this research study. Aspirin is the standard of care blood thinner used for stroke prevention in ischemic stroke patients without atrial fibrillation.

Principal Investigator(s)
Rodney Short, MD
National Institutes of Health
Genesis Research at 563-421-3941


  • Genesis Medical Center, West Central Park
    1401 West Central Park Avenue
    Davenport, IA 52804
    Main: 563-421-1000

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office